Roche Full-Year Report 2023

• Group sales grow by 1% at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidance
• Excluding COVID-19 products, Group sales increased by 8%
• Pharmaceuticals Division sales increase by 6% (excluding COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for newer medicines, with eye medicine Vabysmo continuing to be the top growth driver, followed by Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Polivy (blood cancer)
• Diagnostics Division sales are 13% lower due to high demand for COVID-19 tests in 2022; strong momentum in the Diagnostics Division’s base business continues with an increase of 7%

Highlights in the fourth quarter of 2023 and January 2024:

• • US approval of Vabysmo (retinal vein occlusion, a severe eye disease)
  • US priority review of Xolair (food allergies)
  • EU approval of subcutaneous form of Tecentriq (cancer immunotherapy)
  • Positive phase III data for inavolisib (breast cancer), Xolair (food allergies) and Hemlibra (babies with severe haemophilia A); positive longer-term data for Columvi and Lunsumio (blood cancer); positive long-term data for Kadcyla (breast cancer)
  • US Breakthrough Device Designation for Elecsys NfL test (multiple sclerosis); launch of innovative new assays (hepatitis B and E)
  • Acquisitions of Telavant (inflammatory bowel disease and other immunologic disorders) and Carmot (obesity and other metabolic diseases); acquisition agreement with LumiraDx (point-of-care technology platform)
  • Roche (3rd) and Chugai (2nd) in Dow Jones Sustainability Indices
• IFRS net income increases 7% (-9% in CHF) to CHF 12.4 billion
• Core earnings per share increase by 6% (-9% in CHF)
• Board proposes dividend increase to CHF 9.60
• Change in Board of Directors